Ex-Lilly CEO Josh Bilenker & Ex-Novartis Head of Oncology Jeff Engelman Announce Treeline Biosciences
Two powerhouse executives have joined forces to form a brand new cancer Biotech company. Josh Bilenker, M.D., and…
Browsing Tag
Josh Bilenker, MD, is a business executive and founder in the biotechnology space. He is currently the Chief Executive Officer of Treeline Biosciences which he founded along with Jeff Engelman M.D., Ph.D in September of 2021. Bilenker also serves in a Director role at Sana Biotechnology.
A self-described American healthcare optimist/realist, before launching Treeline, Dr. Josh Bilenker served as CEO of Loxo Oncology at Lilly, Eli Lilly and Company’s cancer research and development group.
Dr. Josh Bilenker joined the Eli Lily team in 2019 after the acquisition of Loxo Oncology, a company he founded and lead as CEO. Previously he worked as a venture capital investor in the biotechnology and healthcare spaces for Aisling Capital as well as serving as a US Food and Drug Administration (FDA) Medical Officer in the FDA Office of Oncologic Diseases (OOD).
His educational background includes the University of Pennsylvania where he studied and earned board certifications in the specialties of internal medicine and medical oncology. Dr. Josh Bilenker received his MD from The Johns Hopkins University School of Medicine along with his AB degree in English from Princeton University.